Lanreotide

BreastfeedingPediatric
  • TRADE NAMES: Somatuline Autogel (Ipsen); Somatuline Depot (Ipsen); Somatuline LA (Ipsen)
  • INDICATIONS: Acromegaly, carcinoid syndrome, thyrotrophic adenoma
  • CLASS: Somatostatin analog
  • HALF-LIFE: 2 hours (immediate release) 5 days (sustained release).
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Antidiabetics, Bromocriptine, Cyclosporine, Insulin, Metformin, Repaglinide, Sulfonylureas

PREGNANCY CATEGORY: C

Our database has 41 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC
LOCAL
OTHER


Page last updated 03/06/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric